Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10962720 | Vaccine | 2016 | 8 Pages |
Abstract
Intranasal vaccination with inactivated influenza viral antigens is an attractive and valid alternative to currently available influenza (flu) vaccines; many of which seem to need efficient and safe adjuvant, however. In this study, we examined whether hydroxypropyl-β-cyclodextrin (HP-β-CD), a widely used pharmaceutical excipient to improve solubility and drug delivery, can act as a mucosal adjuvant for intranasal flu vaccines. We found that intranasal immunization of mice with hemagglutinin split- as well as inactivated whole-virion influenza vaccine with HP-β-CD resulted in secretion of antigen-specific IgA and IgGs in the airway mucosa and the serum as well. As a result, both HP-β-CD adjuvanted-flu intranasal vaccine protected mice against lethal challenge with influenza virus, equivalent to those induced by experimental cholera toxin-adjuvanted ones. Of note, intranasal use of HP-β-CD as an adjuvant induced significantly lower antigen-specific IgE responses than that induced by aluminum salt adjuvant. These results suggest that HP-β-CD may be a potent mucosal adjuvant for seasonal and pandemic influenza vaccine.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Takato Kusakabe, Koji Ozasa, Shingo Kobari, Masatoshi Momota, Natsuko Kishishita, Kouji Kobiyama, Etsushi Kuroda, Ken J. Ishii,